Drugs in the Pipeline
Dapagliflozin Under Review for Chronic Kidney Disease
The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.
Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and 300 or greater vs <50 units/kg/week